{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:46:55Z","timestamp":1794019615483,"version":"4.8.0"},"reference-count":111,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.ejmech.2023.115175","type":"journal-article","created":{"date-parts":[[2023,2,7]],"date-time":"2023-02-07T03:06:00Z","timestamp":1675739160000},"page":"115175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"special_numbering":"C","title":["Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers"],"prefix":"10.1016","volume":"250","author":[{"given":"Yishi","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbin","family":"Kuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2613-941X","authenticated-orcid":false,"given":"Peng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib1","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/nm.3893","article-title":"Inflammasomes: mechanism of action, role in disease, and therapeutics [J]","volume":"21","author":"Guo","year":"2015","journal-title":"Nat. Med."},{"issue":"7640","key":"10.1016\/j.ejmech.2023.115175_bib2","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/nature21363","article-title":"Inflammation, metaflammation and immunometabolic disorders [J]","volume":"542","author":"Hotamisligil","year":"2017","journal-title":"Nature"},{"issue":"7237","key":"10.1016\/j.ejmech.2023.115175_bib3","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nature07683","article-title":"Genetic architecture of mouse skin inflammation and tumour susceptibility [J]","volume":"458","author":"Quigley","year":"2009","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib4","doi-asserted-by":"crossref","first-page":"e180","DOI":"10.1016\/S2214-109X(19)30488-7","article-title":"Global burden of cancer attributable to infections in 2018: a worldwide incidence analysis [J]","volume":"8","author":"De Martel","year":"2020","journal-title":"Lancet Global Health"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1001\/jamaoncol.2022.0494","article-title":"The potential of the gut microbiome to reshape the cancer therapy paradigm: a review [J]","volume":"8","author":"Liu","year":"2022","journal-title":"JAMA Oncol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib6","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/aam.aam_56_18","article-title":"Inflammation and cancer [J]","volume":"18","author":"Singh","year":"2019","journal-title":"Ann. Afr. Med."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115175_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/s11892-015-0638-x","article-title":"The CXCR1\/2 pathway: involvement in diabetes pathophysiology and potential target for T1D interventions [J]","volume":"15","author":"Citro","year":"2015","journal-title":"Curr. Diabetes Rep."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib8","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23042168","article-title":"CXCR2 receptor: regulation of expression, signal transduction, and involvement in cancer [J]","volume":"23","author":"Korbecki","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.ejmech.2023.115175_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-directed tumor microenvironment modulation in cancer immunotherapy [J]","volume":"22","author":"Bule","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib10","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1084\/jem.169.3.1185","article-title":"Identification and characterization of specific receptors for monocyte-derived neutrophil chemotactic factor (MDNCF) on human neutrophils [J]","volume":"169","author":"Samanta","year":"1989","journal-title":"J. Exp. Med."},{"issue":"34","key":"10.1016\/j.ejmech.2023.115175_bib11","doi-asserted-by":"crossref","first-page":"20545","DOI":"10.1074\/jbc.271.34.20545","volume":"271","author":"Ahuja","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib12","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1021\/bi001661b","article-title":"Identification of a motif in the carboxyl terminus of CXCR2 that is involved in adaptin 2 binding and receptor internalization [J]","volume":"40","author":"Fan","year":"2001","journal-title":"Biochemistry"},{"issue":"7823","key":"10.1016\/j.ejmech.2023.115175_bib13","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/s41586-020-2492-5","article-title":"Structural basis of CXC chemokine receptor 2 activation and signalling [J]","volume":"585","author":"Liu","year":"2020","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib14","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22020843","article-title":"The effect of hypoxia on the expression of CXC chemokines and CXC chemokine receptors-A review of literature [J]","volume":"22","author":"Korbecki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12 Pt 1","key":"10.1016\/j.ejmech.2023.115175_bib15","first-page":"6390","article-title":"Characterization of autostimulatory and transforming growth factors from human melanoma cells [J]","volume":"45","author":"Richmond","year":"1985","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.ejmech.2023.115175_bib16","doi-asserted-by":"crossref","first-page":"7732","DOI":"10.1073\/pnas.87.19.7732","article-title":"Identification of three related human GRO genes encoding cytokine functions [J]","volume":"87","author":"Haskill","year":"1990","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/jlb.67.1.53","article-title":"The tumorigenic and angiogenic effects of MGSA\/GRO proteins in melanoma [J]","volume":"67","author":"Haghnegahdar","year":"2000","journal-title":"J. Leukoc. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib18","first-page":"1036","article-title":"Complementary action of CXCL1 and CXCL8 in pathogenesis of gastric carcinoma [J]","volume":"11","author":"Chen","year":"2018","journal-title":"Int. J. Clin. Exp. Pathol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s10456-014-9454-1","article-title":"CXCL1 promotes arteriogenesis through enhanced monocyte recruitment into the peri-collateral space","volume":"18","author":"Vries","year":"2015","journal-title":"[J]. Angiogenesis"},{"key":"10.1016\/j.ejmech.2023.115175_bib20","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nbd.2017.06.001","article-title":"CXCL1\/CXCR2 signaling in pathological pain: role in peripheral and central sensitization [J]","volume":"105","author":"Silva","year":"2017","journal-title":"Neurobiol. Dis."},{"issue":"2\u20133","key":"10.1016\/j.ejmech.2023.115175_bib21","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cac2.12010","article-title":"CXCL5\/CXCR2 axis in tumor microenvironment as potential diagnostic biomarker and therapeutic target","volume":"40","author":"Zhang","year":"2020","journal-title":"[J]. Cancer commun. (London, England)"},{"issue":"11","key":"10.1016\/j.ejmech.2023.115175_bib22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1007\/s00432-007-0225-x","article-title":"CXCL5 overexpression is associated with late stage gastric cancer [J]","volume":"133","author":"Park","year":"2007","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/BF03256304","article-title":"CXCL5 gene polymorphism association with diabetes mellitus [J]","volume":"12","author":"Hasani Ranjbar","year":"2008","journal-title":"Mol. Diagn. Ther."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115175_bib24","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1038\/sj.bjc.6603177","article-title":"Production and upregulation of granulocyte chemotactic protein-2\/CXCL6 by IL-1 beta and hypoxia in small cell lung cancer [J]","volume":"94","author":"Zhu","year":"2006","journal-title":"Br. J. Cancer"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib25","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1165\/rcmb.2015-0245OC","article-title":"Platelet-specific chemokines contribute to the pathogenesis of acute lung injury [J]","volume":"56","author":"Bdeir","year":"2017","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib26","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/cam4.1292","article-title":"CTAPIII\/CXCL7: a novel biomarker for early diagnosis of lung cancer [J]","volume":"7","author":"Du","year":"2018","journal-title":"Cancer Med."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib27","first-page":"627","article-title":"Induction of interleukin-8 (CXCL-8) by tumor necrosis factor-alpha and leukemia inhibitory factor in pancreatic carcinoma cells: impact of CXCL-8 as an autocrine growth factor [J]","volume":"31","author":"Kamohara","year":"2007","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejmech.2023.115175_bib28","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.bone.2014.01.015","article-title":"Circulating interleukin-8 levels explain breast cancer osteolysis in mice and humans [J]","volume":"61","author":"Kamalakar","year":"2014","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.lungcan.2006.11.014","article-title":"Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation [J]","volume":"56","author":"Luppi","year":"2007","journal-title":"Lung Cancer"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/pros.20223","article-title":"Expression of interleukin-8 gene in radical prostatectomy specimens is associated with advanced pathologic stage [J]","volume":"64","author":"Uehara","year":"2005","journal-title":"Prostate"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00008390-199506000-00006","article-title":"Serum interleukin-8 (IL-8) is elevated in patients with metastatic melanoma and correlates with tumour load [J]","volume":"5","author":"Scheibenbogen","year":"1995","journal-title":"Melanoma Res."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib32","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1124\/jpet.108.143826","article-title":"Chemotherapy-induced CXC-chemokine\/CXC-chemokine receptor signaling in metastatic prostate cancer cells confers resistance to oxaliplatin through potentiation of nuclear factor-kappaB transcription and evasion of apoptosis [J]","volume":"327","author":"Wilson","year":"2008","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"Supplement 1","key":"10.1016\/j.ejmech.2023.115175_bib33","doi-asserted-by":"crossref","first-page":"249","DOI":"10.2337\/db20-249-OR","article-title":"249-OR: a randomized, double-blind phase 2 trial of the CXCR1\/2 inhibitor ladarixin in adult patients with new-onset type 1","volume":"69","author":"Bosi","year":"2020","journal-title":"Diabetes J."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib34","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.iac.2014.07.002","article-title":"Metabolic asthma: is there a link between obesity, diabetes, and asthma?","volume":"34","author":"Perez","year":"2014","journal-title":"[J]. Immunol. allergy clin. North Am."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115175_bib35","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrneurol.2010.130","article-title":"How does diabetes accelerate Alzheimer disease pathology?","volume":"6","author":"Sims-Robinson","year":"2010","journal-title":"[J]. Nat. rev. Neurol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib36","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/156800908783497159","article-title":"Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery [J]","volume":"8","author":"Cheng","year":"2008","journal-title":"Curr. Cancer Drug Targets"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib37","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1073\/pnas.94.7.3052","article-title":"Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases [J]","volume":"94","author":"Knall","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1158\/1541-7786.MCR-07-0032","article-title":"Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells [J]","volume":"5","author":"Macmanus","year":"2007","journal-title":"Mol. Cancer Res. : MCR"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib39","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.cell.2007.11.028","article-title":"Calcium signaling [J]","volume":"131","author":"Clapham","year":"2007","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib40","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1165\/ajrcmb.17.1.f132","article-title":"The role of nuclear factor-kappa B in cytokine gene regulation [J]","volume":"17","author":"Blackwell","year":"1997","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115175_bib41","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1038\/sj.onc.1208442","article-title":"KSHV-GPCR and CXCR2 transforming capacity and angiogenic responses are mediated through a JAK2-STAT3-dependent pathway [J]","volume":"24","author":"Burger","year":"2005","journal-title":"Oncogene"},{"issue":"12","key":"10.1016\/j.ejmech.2023.115175_bib42","doi-asserted-by":"crossref","first-page":"6714","DOI":"10.4049\/jimmunol.171.12.6714","article-title":"IL-8-mediated cell migration in endothelial cells depends on cathepsin B activity and transactivation of the epidermal growth factor receptor [J]","volume":"171","author":"Schraufstatter","year":"2003","journal-title":"J. Immunol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib43","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.7150\/thno.15625","article-title":"Role of the CXCL8-CXCR1\/2 Axis in cancer and inflammatory diseases [J]","volume":"7","author":"Ha","year":"2017","journal-title":"Theranostics"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115175_bib44","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.RES.84.5.489","article-title":"Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis [J]","volume":"84","author":"Schmidt","year":"1999","journal-title":"Circ. Res."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib45","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2353\/ajpath.2006.040748","article-title":"Up-regulated expression of the CXCR2 ligand KC\/GRO-alpha in atherosclerotic lesions plays a central role in macrophage accumulation and lesion progression [J]","volume":"168","author":"Boisvert","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib46","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1152\/ajpendo.00513.2014","article-title":"Excessive secretion of IL-8 by skeletal muscle in type 2 diabetes impairs tube growth: potential role of PI3K and the Tie 2 receptor [J]","volume":"309","author":"Amir Levy","year":"2015","journal-title":"Am. J. Physiol. Endocrinol. Metabol."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib47","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1002\/emmm.201201717","article-title":"Distinct functions of chemokine receptor axes in the atherogenic mobilization and recruitment of classical monocytes [J]","volume":"5","author":"Soehnlein","year":"2013","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ejmech.2023.115175_bib48","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.cyto.2017.07.012","article-title":"Proinflammatory cytokine MIF plays a role in the pathogenesis of type-2 diabetes mellitus, but does not affect hepatic mitochondrial function [J]","volume":"99","author":"Rodriguez-Sosa","year":"2017","journal-title":"Cytokine"},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib49","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.pharmthera.2008.10.005","article-title":"CXCR2 antagonists for the treatment of pulmonary disease [J]","volume":"121","author":"Chapman","year":"2009","journal-title":"Pharmacol. Ther."},{"issue":"10 Pt 2","key":"10.1016\/j.ejmech.2023.115175_bib50","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1164\/ajrccm.164.supplement_2.2106065","article-title":"Angiogenesis and remodeling of airway vasculature in chronic inflammation [J]","volume":"164","author":"Mcdonald","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib51","doi-asserted-by":"crossref","first-page":"3348","DOI":"10.4049\/jimmunol.170.6.3348","article-title":"CXCR2 regulates respiratory syncytial virus-induced airway hyperreactivity and mucus overproduction [J]","volume":"170","author":"Miller","year":"2003","journal-title":"J. Immunol."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115175_bib52","doi-asserted-by":"crossref","first-page":"C957","DOI":"10.1152\/ajpcell.00451.2005","article-title":"Interleukin-8: novel roles in human airway smooth muscle cell contraction and migration [J]","volume":"291","author":"Govindaraju","year":"2006","journal-title":"Am. J. Physiol. Cell Physiol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib53","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.4049\/jimmunol.1301538","article-title":"IL-17A promotes the exacerbation of IL-33-induced airway hyperresponsiveness by enhancing neutrophilic inflammation via CXCR2 signaling in mice [J]","volume":"192","author":"Mizutani","year":"2014","journal-title":"J. Immunol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib54","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1038\/nrd4025","article-title":"New anti-inflammatory targets for chronic obstructive pulmonary disease [J]","volume":"12","author":"Barnes","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib55","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1007\/s00281-016-0561-5","article-title":"COPD immunopathology [J]","volume":"38","author":"Caramori","year":"2016","journal-title":"Semin. Immunopathol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib56","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1378\/chest.123.4.1240","article-title":"Neutrophil chemotactic activity of sputum from patients with COPD: role of interleukin 8 and leukotriene B4 [J]","volume":"123","author":"Beeh","year":"2003","journal-title":"Chest"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115175_bib57","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1164\/rccm.200208-794OC","article-title":"Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease [J]","volume":"168","author":"Qiu","year":"2003","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.115175_bib58","volume":"vol. 1866","author":"Zhu","year":"2020"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115175_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12082076","article-title":"Prognostic value of CXCR2 in breast cancer [J]","volume":"12","author":"Boissi\u00e8re-Michot","year":"2020","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib60","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1053\/j.gastro.2022.06.024","article-title":"METTL3 inhibits antitumor immunity by targeting m(6)a-BHLHE41-CXCL1\/CXCR2 Axis to promote colorectal cancer [J]","volume":"163","author":"Chen","year":"2022","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib61","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1517\/14728222.2013.772137","article-title":"CXCR2: a target for pancreatic cancer treatment? [J]","volume":"17","author":"Hertzer","year":"2013","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.ejmech.2023.115175_bib62","volume":"vol. 20","author":"Cheng","year":"2021"},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib63","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma [J]","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2023.115175_bib64","first-page":"1543","volume":"vol. 7","author":"Ha","year":"2017"},{"key":"10.1016\/j.ejmech.2023.115175_bib65","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clim.2016.08.004","article-title":"Changes of regulatory T cells, transforming growth factor-beta and interleukin-10 in patients with type 1 diabetes mellitus: a systematic review and meta-analysis [J]","volume":"170","author":"Qiao","year":"2016","journal-title":"Clin. Immunol."},{"issue":"10","key":"10.1016\/j.ejmech.2023.115175_bib66","doi-asserted-by":"crossref","first-page":"4106","DOI":"10.1172\/JCI42754","article-title":"Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma [J]","volume":"121","author":"Ijichi","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib67","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.canlet.2005.10.041","article-title":"Blockade of the chemokine receptor CXCR2 inhibits pancreatic cancer cell-induced angiogenesis [J]","volume":"241","author":"Wente","year":"2006","journal-title":"Cancer Lett."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115175_bib68","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ccr.2004.09.028","article-title":"Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis [J]","volume":"6","author":"Sparmann","year":"2004","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib69","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2010.11.058","article-title":"Overexpression of CXCL5 is associated with poor survival in patients with pancreatic cancer [J]","volume":"178","author":"Li","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib70","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/sj.onc.1206113","article-title":"IL-8 expression and its possible relationship with estrogen-receptor-negative status of breast cancer cells [J]","volume":"22","author":"Freund","year":"2003","journal-title":"Oncogene"},{"issue":"16","key":"10.1016\/j.ejmech.2023.115175_bib71","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1016\/j.ejca.2004.05.024","article-title":"Different signalling pathways regulate VEGF and IL-8 expression in breast cancer: implications for therapy [J]","volume":"40","author":"Chelouche-Lev","year":"2004","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ejmech.2023.115175_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2017.09.030","article-title":"CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2 [J]","volume":"412","author":"Xu","year":"2018","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib73","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1158\/2159-8290.CD-21-0369","article-title":"Combined inhibition of SHP2 and CXCR1\/2 promotes antitumor T-cell response in NSCLC [J]","volume":"12","author":"Tang","year":"2022","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ejmech.2023.115175_bib74","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/1742-2094-8-171","article-title":"Neuroinflammation in Alzheimer's disease wanes with age [J]","volume":"8","author":"Hoozemans","year":"2011","journal-title":"J. Neuroinflammation"},{"issue":"9","key":"10.1016\/j.ejmech.2023.115175_bib75","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1001\/jamaneurol.2016.2078","article-title":"Evaluation of tau imaging in staging alzheimer disease and revealing interactions between \u03b2-amyloid and tauopathy [J]","volume":"73","author":"Wang","year":"2016","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.ejmech.2023.115175_bib76","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/s41593-022-01084-8","article-title":"Faulty autolysosome acidification in Alzheimer's disease mouse models induces autophagic build-up of A\u03b2 in neurons, yielding senile plaques [J]","volume":"25","author":"Lee","year":"2022","journal-title":"Nat. Neurosci."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib77","first-page":"201","volume":"16","author":"Dutton","year":"1998","journal-title":"T CELL MEMORY [J]"},{"key":"10.1016\/j.ejmech.2023.115175_bib78","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12974-015-0339-z","article-title":"Pharmacological antagonism of interleukin-8 receptor CXCR2 inhibits inflammatory reactivity and is neuroprotective in an animal model of Alzheimer's disease [J]","volume":"12","author":"Ryu","year":"2015","journal-title":"J. Neuroinflammation"},{"issue":"18","key":"10.1016\/j.ejmech.2023.115175_bib79","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202100275","article-title":"Emerging targets in type 2 diabetes and diabetic complications [J]","volume":"8","author":"Demir","year":"2021","journal-title":"Adv. Sci."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib80","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1007\/s00401-015-1518-9","article-title":"Immunotherapies in Alzheimer's disease: too much, too little, too late or off-target? [J]","volume":"131","author":"St-Amour","year":"2016","journal-title":"Acta Neuropathol."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115175_bib81","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1074\/jbc.273.17.10095","article-title":"Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration [J]","volume":"273","author":"White","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"23","key":"10.1016\/j.ejmech.2023.115175_bib82","doi-asserted-by":"crossref","first-page":"8102","DOI":"10.1016\/j.bmc.2009.09.051","article-title":"Structural optimization of a CXCR2-directed antagonist that indirectly inhibits gamma-secretase and reduces Abeta [J]","volume":"17","author":"Bakshi","year":"2009","journal-title":"Bioorg. Med. Chem."},{"issue":"17","key":"10.1016\/j.ejmech.2023.115175_bib83","doi-asserted-by":"crossref","first-page":"10095","DOI":"10.1074\/jbc.273.17.10095","article-title":"Identification of a potent, selective non-peptide CXCR2 antagonist that inhibits interleukin-8-induced neutrophil migration [J]","volume":"273","author":"White","year":"1998","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2023.115175_bib84","article-title":"Antitumor and radiosensitization effects of a CXCR2 inhibitor in nasopharyngeal carcinoma","volume":"9","author":"Liu","year":"2021","journal-title":"Frontiers in Cell and Developmental Biology"},{"key":"10.1016\/j.ejmech.2023.115175_bib85","series-title":"CXCR2, a Novel Target to Overcome Tyrosine Kinase Inhibitor Resistance in Chronic Myelogenous Leukemia Cells [J]","author":"Kim","year":"2021"},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1124\/jpet.117.240705","article-title":"Danirixin: a reversible and selective antagonist of the CXC chemokine receptor 2 [J]","volume":"362","author":"Busch-Petersen","year":"2017","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib87","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1124\/jpet.114.221358","article-title":"Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist [J]","volume":"353","author":"Nicholls","year":"2015","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.ejmech.2023.115175_bib88","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.pupt.2015.02.001","article-title":"The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD [J]","volume":"31","author":"Kirsten","year":"2015","journal-title":"Pulm. Pharmacol. Therapeut."},{"issue":"9","key":"10.1016\/j.ejmech.2023.115175_bib89","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1164\/rccm.201405-0992OC","article-title":"CXCR2 antagonist MK-7123. A phase 2 proof-of-concept trial for chronic obstructive pulmonary disease [J]","volume":"191","author":"Rennard","year":"2015","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ejmech.2023.115175_bib90","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s40360-015-0017-x","article-title":"The pharmacokinetics and pharmacodynamics of danirixin (GSK1325756)--a selective CXCR2 antagonist --in healthy adult subjects [J]","volume":"16","author":"Miller","year":"2015","journal-title":"BMC pharmacol. toxicol."},{"issue":"14","key":"10.1016\/j.ejmech.2023.115175_bib91","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1016\/j.bmcl.2007.05.011","article-title":"3-Arylamino-2H-1,2,4-benzothiadiazin-5-ol 1,1-dioxides as novel and selective CXCR2 antagonists [J]","volume":"17","author":"Wang","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"20","key":"10.1016\/j.ejmech.2023.115175_bib92","doi-asserted-by":"crossref","first-page":"8378","DOI":"10.1021\/jm500827t","article-title":"Discovery of 2-[5-(4-Fluorophenylcarbamoyl)pyridin-2-ylsulfanylmethyl]phenylboronic acid (SX-517): noncompetitive boronic acid antagonist of CXCR1 and CXCR2 [J]","volume":"57","author":"Maeda","year":"2014","journal-title":"J. Med. Chem."},{"issue":"26","key":"10.1016\/j.ejmech.2023.115175_bib93","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1021\/jm0609622","article-title":"Discovery of 2-hydroxy-N,N-dimethyl-3-{2-[[(R)-1-(5- methylfuran-2-yl)propyl]amino]-3,4-dioxocyclobut-1-enylamino}benzamide (SCH 527123): a potent, orally bioavailable CXCR2\/CXCR1 receptor antagonist [J]","volume":"49","author":"Dwyer","year":"2006","journal-title":"J. Med. Chem."},{"issue":"8","key":"10.1016\/j.ejmech.2023.115175_bib94","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1021\/acs.jcim.5b00181","article-title":"Discovery of novel CXCR2 inhibitors using ligand-based pharmacophore models [J]","volume":"55","author":"Ha","year":"2015","journal-title":"J. Chem. Inf. Model."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib95","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1365-2222.2012.04014.x","article-title":"Safety and efficacy of a CXCR2 antagonist in patients with severe asthma and sputum neutrophils: a randomized, placebo-controlled clinical trial [J]","volume":"42","author":"Nair","year":"2012","journal-title":"Clin. Exp. Allergy : j. Br. Soc. Allergy Clin. Immunol."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib96","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.canlet.2010.10.004","article-title":"Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases [J]","volume":"300","author":"Varney","year":"2011","journal-title":"Cancer Lett."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib97","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1158\/1078-0432.CCR-08-2387","article-title":"Small-molecule antagonists for CXCR2 and CXCR1 inhibit human melanoma growth by decreasing tumor cell proliferation, survival, and angiogenesis [J]","volume":"15","author":"Singh","year":"2009","journal-title":"Clin. Cancer Res. : off. j. Am. Assoc. Cancer Res."},{"issue":"11","key":"10.1016\/j.ejmech.2023.115175_bib98","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1016\/j.bmcl.2015.04.041","article-title":"Boronic acid-containing CXCR1\/2 antagonists: optimization of metabolic stability, in vivo evaluation, and a proposed receptor binding model [J]","volume":"25","author":"Maeda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2023.115175_bib99","article-title":"Inhibition of MDSC trafficking with SX-682, a CXCR1\/2 inhibitor, enhances NK-cell immunotherapy in head and neck cancer models","volume":"6","author":"Greene","year":"2020","journal-title":"Clinical Cancer Research"},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126853","article-title":"Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy [J]","volume":"4","author":"Sun","year":"2019","journal-title":"JCI insight"},{"issue":"32","key":"10.1016\/j.ejmech.2023.115175_bib101","doi-asserted-by":"crossref","first-page":"11791","DOI":"10.1073\/pnas.0402090101","article-title":"Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury [J]","volume":"101","author":"Bertini","year":"2004","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"3","key":"10.1016\/j.ejmech.2023.115175_bib102","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/sc.2010.127","article-title":"Inhibition of CXCR1 and CXCR2 chemokine receptors attenuates acute inflammation, preserves gray matter and diminishes autonomic dysreflexia after spinal cord injury [J]","volume":"49","author":"Marsh","year":"2011","journal-title":"Spinal Cord"},{"issue":"5","key":"10.1016\/j.ejmech.2023.115175_bib103","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1111\/j.1523-1755.2005.00272.x","article-title":"Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia\/reperfusion [J]","volume":"67","author":"Cugini","year":"2005","journal-title":"Kidney Int."},{"issue":"1","key":"10.1016\/j.ejmech.2023.115175_bib104","first-page":"35","article-title":"Development of a systemically-active dual CXCR1\/CXCR2 allosteric inhibitor and its efficacy in a model of transient cerebral ischemia in the rat [J]","volume":"17","author":"Garau","year":"2006","journal-title":"Eur. Cytokine Netw."},{"issue":"2","key":"10.1016\/j.ejmech.2023.115175_bib105","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1476-5381.2011.01566.x","article-title":"Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1\/CXCR2 non-competitive allosteric inhibitor [J]","volume":"165","author":"Bertini","year":"2012","journal-title":"Br. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.ejmech.2023.115175_bib106","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/j.1365-2222.2011.03921.x","article-title":"Airway inflammation evaluated in a human nasal lipopolysaccharide challenge model by investigating the effect of a CXCR2 inhibitor [J]","volume":"42","author":"Virtala","year":"2012","journal-title":"Clin. Exp. Allergy"},{"issue":"8","key":"10.1016\/j.ejmech.2023.115175_bib107","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1124\/dmd.119.087163","article-title":"Plasma protein binding as an optimizable parameter for acidic drugs [J]","volume":"47","author":"Gardiner","year":"2019","journal-title":"Drug Metabol. Dispos.: biol. fate chem."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib108","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1016\/j.bmcl.2015.01.067","article-title":"Discovery and evaluation of a novel monocyclic series of CXCR2 antagonists [J]","volume":"25","author":"Austin","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"12","key":"10.1016\/j.ejmech.2023.115175_bib109","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3109\/00498254.2016.1152522","article-title":"Strategies toward optimization of the metabolism of a series of serotonin-4 partial agonists: investigation of azetidines as piperidine isosteres [J]","volume":"46","author":"Obach","year":"2016","journal-title":"Xenobiotica fate foreign compd biol. syst."},{"issue":"5","key":"10.1016\/j.ejmech.2023.115175_bib110","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1124\/mol.107.044610","article-title":"Identification of a putative intracellular allosteric antagonist binding-site in the CXC chemokine receptors 1 and 2 [J]","volume":"74","author":"Nicholls","year":"2008","journal-title":"Mol. Pharmacol."},{"issue":"7","key":"10.1016\/j.ejmech.2023.115175_bib111","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/j.1476-5381.2009.00623.x","article-title":"A common intracellular allosteric binding site for antagonists of the CXCR2 receptor [J]","volume":"159","author":"Salchow","year":"2010","journal-title":"Br. J. Pharmacol."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523423000909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:49:05Z","timestamp":1759330145000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523423000909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":111,"alternative-id":["S0223523423000909"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115175","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Expanding role of CXCR2 and therapeutic potential of CXCR2 antagonists in inflammatory diseases and cancers","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2023.115175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"115175"}}